Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Abbott Laboratories ($ABT) announced that it has launched its Proclaim DRG Neurostimulation System in Europe. The system is designed to deliver dorsal root ganglion stimulation to patients with chronic neuropathic pain. The system is magnetic resonance conditional. It is also recharge free and is easy to use as it uses an iPod touch mobile device as its controller.
The company also announced that its ACCURATE study shows that its dorsal root ganglion stimulation therapy has advantages over traditional spinal cord stimulation treating patients suffering from complex regional pain syndrome. The company stock has gained 6% on Year to Date basis. Its latest announcements are likely to push stock prices further up.

Apricus Biosciences ($APRI) announced that its commercialization partner Ferring Pharmaceuticals has received regulatory approval in Mexico for Vitaros, an on-demand topical cream to treat men with erectile dysfunction. Now, the product is approved in 26 countries globally. However, it is only the second country, after Argentina, in Latin America to approve.
The company is likely to see improved prospects with the approval. Apricus Biosciences has a distribution deal with Ferring. Under the deal, Apricus received upfront payment of $4.5 million. It also received regulatory milestone payment of $1.6 million. The company is further eligible for receiving up to $28 million in payments upon hitting milestones.


• Allergan ($AGN) has agreed to pay a $15 million penalty and admit to wrongdoing for failing to disclose 2014 merger talks with Actavis.
• Neurocrine Biosciences ($NBIX) announced that valbenazine, branded as INGREZZA, failed to achieve its primary endpoint in a Phase 2 study, T-Forward, in adults with Tourette syndrome.

• Chembio Diagnostics' ($CEMI) announced that its DPP HIV-Syphilis point-of-care combination assay has received CE Mark certification.
• Teva Pharmaceuticals Industries ($TEVA) received FDA approval for its VANTRELA ER (hydrocodone bitartrate) extended-release tablets for the management of pain.

• Mallinckrodt (NYSE:MNK) has agreed to pay $100M to settle FTC and state charges that it used its monopoly to increase the price of Acthar gel by 2,165%.
• Takeda Pharmaceutical ($TKPYY) inks a global collaboration agreement with Ovid Therapeutics for developing and commercializing Takeda's Phase 1-stage TAK-935 to treat rare pediatric epilepsies.

• Iradimed Corporation ($IRMD) announced that it expects its year 2017 revenue to be in the range of $23.9 million and $24.3 million. Its EPS is likely to be in the range of $0.07 and $0.08.

• Anthem ($ANTM) Receives Buy rating from Oppenheimer. The price target for the stock has been set at $163.
• Envision Healthcare ($EVHC) Receives Buy rating from Oppenheimer. The price target for the stock has been set at $87.

Gainers (% price change) Last Trade Change Mkt Cap
CyberOptics Corporation
38.95 +5.30 (15.75%) 266.10M
Immunomedics, Inc.
4.17 +0.28 (7.20%) 441.78M
AMAG Pharmaceuticals, Inc
24.70 +1.35 (5.78%) 857.84M
Insys Therapeutics Inc
10.83 +0.53 (5.15%) 777.27M
Neurocrine Biosciences
42.04 +1.87 (4.66%) 3.47B
Losers (% price change)
CTI BioPharma Corp
5.17 -0.28 (-5.14%) 141.03M
Community Health Systems
6.82 -0.29 (-4.08%) 795.52M
ImmunoGen, Inc.
2.46 -0.10 (-3.91%) 226.25M
Tenet Healthcare Corp
18.44 -0.55 (-2.90%) 1.91B
56.55 -1.62 (-2.78%) 13.14B
Most Actives (dollar volume)
UnitedHealth Group Inc
157.74 -2.92 (-1.82%) 149.08B
Gilead Sciences, Inc.
72.13 +0.22 (0.31%) 95.03B
Pfizer Inc.
32.03 -0.03 (-0.09%) 191.62B
Johnson & Johnson
114.70 -0.17 (-0.15%) 312.78B
Merck & Co., Inc.
61.17 -0.31 (-0.50%) 166.33B